PRME Prime Medicine, Inc.

NASDAQ
$3.84

Prime Medicine, Inc. (PRME) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.2% since its last earnings release on November 12, 2026.

Prime Medicine Beat Consensus Estimates
Thursday, November 12, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · After Close
Earnings Whisper
-
vs ($0.22)
Rev est $12.67M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.13

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Prime Medicine, Inc.

Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.